



To:  Sarah Ewing 
AIChE Student Programs 
From: Engineering Design Team  
Date: March 9th, 2016 
Subject: Letter of Transmittal 
 
Enclosed is the report for the Cell Therapy for Spinal Cord Injuries: Commercial Manufacturing 
Facility to be submitted to the 2016 AIChE Student Design Competition. The project was to 
develop a stem cell manufacturing facility for the production of these cells to be used in the 
treatment of spinal cord injuries. 
In this report, a manufacturing facility is designed with the ability to readily scale-up production 
to meet market demands. This is achieved by having up to four bio-reactor trains per module 
and the option to operate each bio-reactor between high and low production rates.  
This facility was designed to be in compliance with current good manufacturing practices and 
current good tissue practices as set by the United States Food and Drug Administration. This is 
to ensure the health and safety of not only those individuals working at the facility but also the 
patients who receive the cell therapy from this company. 
Please be aware that this report is concise. It is understood that management has limited time, 
and so every attempt was made to efficiently communicate the design process in a clear 
fashion without extraneous information.  
This report is the preliminary design, economic analysis, and subsequent recommendation on 
how to proceed.  
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This project was undertaken to provide a preliminary design of a facility that could manufacture 
stem cells for treatment of spinal cord injuries. The result of this design is a module facility that 
is capable of meeting the IRR of 50% at reasonable treatment prices even with low production.  
It is recommended that management move this preliminary design forwarded to detailed 
design as quickly as possible. It is also recommended that a facet of the detailed design is a pilot 
test to validate that the number of treatments produced per batch matches the expectation set 
by the literature.  
The facility is a module concept that allows for varied treatment production rates per bio-
reactor train. It is also developed to accommodate up to three more bio-reactor trains per 
module with a slight increase in capital investment for each added train.  
Table 1: Treatment Price Summary 
  
Table 1 shows three different operational scenarios for the facility. Scenario 1 is a single bio-
reactor train operating in a module at low production. This is the fewest amount of treatments 
that the facility would expect to produce. Scenario 2 takes the single bio-reactor train in the 
module and increases it to high production by reducing the amount of downtime between each 
manufacturing campaign. The amount of treatments produced is more than tripled and the 
price per treatment has dropped significantly. Scenario 3 showcases the facility operating at 
maximum capacity with four bio-reactor trains in the module at high production. It provides 
more than 12 times the original amount of annual treatments and at nearly 80% less than the 
initial treatment cost. 
Extensive research has been done to ensure that the design is as accurate as possible to what 
should be expected in a manufacturing scale-up. Additionally, the sensitivity analysis done with 
a Monte Carlo simulation shows a stable economic projection in which small discrepancies 
cause little impact on the price per treatment 75% of the time. In 95% of the cases the 
treatment price did not exceed twice the initial price. 
Furthermore, the facility has been designed to follow cGMP and cGTP as set by the FDA. This 
will ensure the health of the workers in the facility and the safety of the patients who receive 
these treatments.  
There are no major health, safety, economic or operational issues in moving forward with this 
design. 
Production Type Annual Treaments Treatment Price Percent Price Reduction
Scenario 1 Low Production, 1 Train 1,485 2,466$                                           -
Scenario 2 High Production, 1 Train 4,471 1,005$                                           59%
Scenario 3 High Production, 4 Train 17,882 508$                                               79%
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This project was initiated by Dr. Robert Beitle, of the Ralph E. Martin Department of Chemical 
Engineering at the University of Arkansas. The project was started on February 8th, 2016. 
The goal of this project is to design a manufacturing facility for the production of stem cells to 
be used in the treatment of spinal cord injuries. This facility is being constructed by a midsized 
company focusing on cell therapy technologies. The standalone assumption has been made for 
economic analysis of the project due to the size of the company and the absence of other 
projects that may have produced taxable revenue which could be reduced by losses incurred 
from this project. 
Adult stem cells differentiated into specialized neural progenitor cells (NPCs) are a potential cell 
therapy for spinal cord injuries1. While adult stem cells that could be used for spinal cord 
injuries are naturally occurring in the human body, they are almost exclusively found in the 
brain2. This would require an expensive and invasive surgery to harvest a limited amount of 
cells to be used for treatment. In lieu of this option, NPCs can be differentiated from either 
human embryonic stem cells (hESC) or adult stem cells called induced pluripotent stem cells 
(iPSC). As the hESC program is behind the iPSC program (and significantly more contentious on 
an ethical level – which provides funding and availability problems), this facility is based on 
using iPSC technology. Therefore, it is assumed that the 1 x 105 vial of adult stem cells contains 
adult stem cells that have been induced into a pluripotent state.  
The facility will be able to receive these cryogenically frozen iPSCs, thaw them, grow them into 
a larger quantity, differentiate them into the desired neural stem cells, purify the cells of 
incorrectly differentiated cells, separate them into the appropriate amount of cells required for 
one treatment and prepare them for shipping to off-site packaging. The facility also has several 
other components that are required for the process. This includes: storage on site for growth 
media and differentiation media, a quality control lab in order to ensure each batch is created 
successfully and is safe for use, storage of the finished product, and a disposal system to 
neutralize all wastes. 
The process was designed to limit the necessity of human interaction while also providing an 
economically priced product. This reduces the risk of exposure to the workers and 
contamination of the cells by the workers.  
When constructing this facility, it was determined that a modular design would be the most 
beneficial while also allowing for operational flexibility. This design allows for high and low 
production rates of up to four bio-reactor trains to be run in parallel. This provides anywhere 
from 1,485 to 17,882 treatments per year per module. This flexibility is built in to allow the 
                                                          
1
 (Ogawa et al., 2002) 
2
 (Zhao, Deng, & Gage, 2008) 
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company to meet market demand as it changes. The current United States market is nearly 
250,000 injured patients with the addition of nearly 12,000 patients a year. The module design 
provides the company the option to easily increase production and eventually manufacture the 
product in larger markets such as Europe or Asia. 
Technical Discussion 
Design Basis 
One of the most significant decisions made in the design process is that iPSCs behave very 
similarly to hESCs3,4.  The design utilizes coefficients, growth conditions, and constraints for 
hESCs and applies them to iPSCs. This seems reasonable as an iPSC is supposed to be an adult 
stem cell reprogrammed to behave as if it were back into its previous embryonic state. 
The market justification for this facility was to meet the demand in the United States market for 
spinal cord injury repair with a long term goal of treating patients in Europe and beyond. The 
current United States market has approximately 250,000 people with spinal cord injuries and an 
additional 12,000 people are injured every year.  
The facility is currently developed to produce 1,485 to 17,882 treatments per module per year 
depending on the number of reactor trains. This treatment amount could allow for a steady 
reduction in injured individuals in the United States. In order to provide the operational 
flexibility to scale up production into larger markets the facility is designed in a modular fashion 
in which a small, standard facility is created with excess capacity so that more reactor trains 
could be located in the same module. The module can have up to three more reactor trains 
added to the original reactor train, bringing the total to four reactor trains, in order to increase 
production while only incurring a slight increase in capital investment and a near proportional 
increase in operating costs. 
Additionally, each reactor train can operate within a range between high and low production. 
Production levels can be changed by reducing the down time of the differentiation reactor (BR-
3).  
                                                          
3
 (Hu et al., 2010) 
4
 (Takahashi et al., 2007) 
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Figure 1: Low Production Gantt Chart 
 
Figure 2: High Production Gantt Chart 
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At high production levels the down time of the BR-3 is reduced to just enough time to allow for 
cleaning and turn around (just under 3 hours) as can be seen in Figure 2: High Production Gantt 
Chart. This design focused on providing both high and low production level estimates in order to 
well define the boundaries of the process. As there are no known technical difficulties with 
operating the reactor trains at some intermediate production level this would be feasible if 
desired by management. The exact operating conditions and costs associated with the selected 
intermediate production level would fall within the operating conditions and costs defined 
between high and low production. 
Furthermore, the module design allows for construction of the module in optimal locations. A 
capital intensive facility constructed in a single location (say California or New York) would be 
challenged to provide treatments that require lengthy shipment distances cross-country let 
alone overseas. This is undesirable due to the delicate nature of the cells. While the cells should 
have a reasonably long shelf-life when frozen, the farther they travel the greater the probability 
becomes that the cells are damaged, contaminated, or killed due to the shipment being 
handled incorrectly. Small, reasonably priced modules can be built it multiple locations across 
the country or overseas to reduce shipment distances. 
Lastly, because the product is a biological one, various restrictions and rules may be imposed by 
different governments and trade organizations on products that are to be imported into their 
domains. Though stem cell treatments are an emerging technology and are not as heavily 
regulated as some of the more developed biological product areas such as organ donations, this 
regulation may occur in the future as stem cell treatments become more readily available5. 
Therefore the ability to construct new facilities that are self-contained within these regulatory 
areas and have the appropriate amount of modules to adequately meet each regions 
production requirements is economically attractive and operationally more efficient.   
Clearly, it is desirable to have the ability to locate facilities close to the markets they will 
service. It is easier, cheaper, and less risky to ensure the safe shipment of the initial adult stem 
cells required to begin the process than it is to ensure the safe shipment of all the treatments 
leaving the facility across equally long distances. 
   
Design Philosophy 
 
This project is focused around the nascent field of large scale production of adult stem cells. 
Thus, the majority of the information contained in this report comes from peer reviewed 
published scientific papers. This provides the best justification for using certain criteria to set 
expectations. It is understood that while some variability may occur in scaling up the process 
                                                          
5
 (Shimazono, 2007) 
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from a laboratory setting to a manufacturing setting the expectation is that the numbers 
provided in the literature will track well on larger scales6.  
While bio-manufacturing facilities have become well developed over the past few decades they 
tend to deal with more rugged cells such as bacteria. This facility, however, deals with adult 
stem cells which require notably more careful treatment than the majority of other bio-
processes. Careful treatment can be seen in the time intensive pouring and pipetting of cellular 
solutions by hand as opposed to the traditional pumping of cellular solutions throughout the 
process. Furthermore, the traditional fermenter reactors used to grow large amounts of cells 
are unable to be used as adult stem cells require an adherent growth environment; such as a 
manifold, a wall, or a microcarrier. Lastly, the cells must be maintained within strict 
environmental conditions for optimal growth and proper differentiation7.  
These special processing requirements for the cells set constraints on several aspects of the 
design. Chief among these is a constraint on the volume of the reactors. As the reactors 
become larger, the ability to maintain consistent environments and the well mixed assumption 
for the cellular solution becomes difficult without increasing the rotational speed of the 
reactors. Increasing rotational speed is problematic. As the rotational speed of the reactors 
exceeds 100 rotations per minute (RPM), cells begin to die due to the sheer forces8. Therefore, 
as reactors become larger it becomes more difficult to prevent thermal or nutrient gradients 
from occurring within the reactor. The increase in volume also makes managing the amount of 
total liquid in the process more difficult. Lastly, due to the exponential nature of cell growth, 
small increases in volume can result in massive increases in total cell treatments produced. This 
causes operational difficulties with managing large number of treatments produced in a single 
batch in a timely manner. 
Another constraint was to reduce the chances of contamination while also minimizing the 
financial impact should contamination ever occur. Chances for contamination are minimized by 
following Current Good Manufacturing Practices (cGMP) as laid out by the Federal Drug 
Administration (FDA). These practices are in place to protect facility personnel and to ensure 
that a safe product is provided to patients. Health and safety were considered throughout the 
design of this facility, more detailed discussion about those considerations can be found in the 




                                                          
6
 (Fernandes et al., 2009) 
7
 (dos Santos, Andrade, da Silva, & Cabral, 2013) 
8
 (Baghbaderani et al., 2008) 




For a graphical representation of this process please consult Figure 3: Process Flow Diagram for 
Stem Cell Facility. For a better understanding of the layout of the clean room please consult 
Figure 4: Clean Room Top Down Layout. These are located at the end of this section. 
The entire manufacturing process occurs within an ISO Class 3 clean room. This is to limit the 
potential for contamination by airborne pathogens or particulates. Technicians will perform all 
tasks using aseptic technique.  
All steps in the process should follow aseptic technique and procedures should be explicit to 
prevent miscommunication or mislabeling of cells in the process. The oxygen levels when 
growing the cells will be 30% of air saturation which results in 8% dissolved oxygen9. The 
oxygen levels when differentiating cells need to be at 4% air saturation which results in 1% 
dissolved oxygen10. Agitation of the cellular solution occurs in the spinner flask and onward.  
The process starts with thawing the 1 x 105 iPSCs. The thawing protocol should follow the 
industry standard, something akin to the one outlined in ThermoFisher Scientifics protocol was 
considered in designing the facility11. 
After the cells have been thawed, they will be plated into Well Plate 1 (WP-1). The well plate is 
then placed within the incubator (I-1) to maintain temperature. The well plate is coated with an 
adherent matrix that allows for cell fixation and growth within the plate.  The cells are in the 
well plate for 7.5 days before they reach the maximum cell density, are cleaved from the well 
plate by the addition of trypsin, and are then transferred to the next system in the bio-reactor 
train. 
The next system in the bio-reactor train is Well Plate 2 (WP-2). This well plate is also located 
within I-1 to maintain temperature. The well plate is also coated with an adherent matrix that 
allows for cell fixation and growth within the plate. The cells are in the well plate for 7.47 days 
before they reach the maximum cell density, are cleaved from the well plate by the addition of 
trypsin, and are then transferred to the next system in the bio-reactor train. 
The next system in the bio-reactor train is Bio-reactor 1 (BR-1) which is a 100 mL spinner flask. 
It will operate at 60 RPM and be stirred with a magnetic stir bar. The flask will sit on a magnetic 
stir plate with a heating element to maintain temperature. Microcarriers are added to the flask 
to provide attachment points and structure for the cells. The cells are in this flask for 4.57 days 
before they reach the maximum cell density and are then transferred to the next system in the 
bio-reactor train. 
                                                          
9
 (Serra et al., 2010) 
10
 (Rodrigues, Fernandes, Diogo, da Silva, & Cabral, 2011) 
11
 (ThermoFisher, 2016) 
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The next system in the bio-reactor train is Bio-reactor 2 (BR-2) which is a 500 mL bio-reactor. It 
will operate at 60 RPM and is stirred by impeller in the reactor. This reactor will have internal 
controls for temperature, dissolved oxygen, and pH monitoring. More microcarriers will be 
added to this reactor to provide more growing area for the cells12. The cells are in this reactor 
for 4.66 days before they reach maximum cell density. 
At this point in the process the adult stem cells have been grown from the starting amount of 1 
X 105 cells to 1.23 X 109 cells. Notice that up until this point in the process the cells have simply 
been grown to larger and larger quantities. During the next step in the bio-reactor system the 
cells will continue to grow and begin to differentiate due to changes in the environment. These 
environmental pressures are differences in the growth factors and other components contained 
in the differentiation media that are not present in the growth media as well as different 
oxygen concentrations13. Ensuring proper conditions are maintained will result in the highest 
yield of stem cells differentiated into NPCs. 
When the cells are finished growing in BR-2 they are collected and cleaved from the 
microcarriers through the addition of trypsin to the solution. The cells are passed through a 40 
micron filter to remove the microcarriers before the cells are moved to the next system in the 
bio-reactor train. 
The next system in the bio-reactor train is Bio-reactor 3 (BR-3) which is the differentiation 
reactor. This reactor uses two different kinds of media in the next two steps of the process. The 
first step is introducing the filtered cells from BR-2 into the system with the addition of neural 
induction media to begin the differentiation of the stem cells into NPCs. This step takes six days 
to allow formation of neural rosettes, which are aggregate embryoid bodies14. BR-3 like BR-2 
will be able to control environmental factors such temperatures, dissolved oxygen, and pH.  
After the formation of the neural rosettes the cellular solution will be filtered and placed back 
into BR-3. The filtration process here is a double filter that has a 400 micron filter and a 100 
micron filter. The double filter allows for everything larger than 400 microns - neural rosette 
formations that grew to larger and will have necrotic cells at the center - and smaller than 100 
microns -neural stem cells that did not form rosettes, damaged adult stem cells, and stem cells 
that differentiated into undesirable forms - to be removed from the cellular solution leaving 
neural rosettes that are in the desired range of 100 to 400 microns in the filter to be replaced 
into BR-315. 
Upon being replaced into BR-3 the filtered neural rosettes will stay in the reactor for another 6 
days. During this time the media will be changed from the neural induction media to rosette 
                                                          
12
 (Bardy et al., 2013) 
13
 (Technologies, 2011) 
14
 (Technologies, 2011) 
15
 (Technologies, 2015) 
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selection media which will break the neural rosettes down and allowing the newly 
differentiated NPCs to separate from themselves16.  
At the conclusion of the second set of six days in BR-3 the purified NPCs are removed from the 
reactor, excess media is removed from the cells (through a combination of decanting and 
centrifugation), the cells are re-suspended in freezing media, and then 2 mL of the solution is 
aliquoted into cryovials which are packed into a thermal regulating container that is placed 
within a refrigerator (F-3) operating at-50°C. The packed cryovials will cool at a rate of 1°/min 
until reaching -50°C. After the cells have reached -50°C they are moved to a nitrogen freezer (F-
4) to be cooled down to -196°C to await pickup17. 
Waste disposal is handled in two parts. The first is liquid wastes that are generated daily from 
the removal of depleted media from the bioreactors and is placed in an autoclave (A-1) to be 
heated up to 121°C for 30 minutes before it is neutralized, if need be, and disposed down the 
drain. The second is solid wastes that are generated from general lab consumables coming into 
contact with cellular material. These wastes are either soaked for 30 minutes in 70% ethanol or 
placed within the in-lab UV cabinet before they are disposed of into the trash. 
Stream Summary Tables and Process Flow Diagram 
 
The stream summary table as seen in Table 2: Stream Summary Table on the next page provides 
information about the streams in the process flow diagram (PFD). In order to perform the mass 
balances in Table 4: Media Mass Balance and Table 5: Cell Mass Balancethe calculations used the 
assumptions listed in the Technical Details and Design Practices section. It should be noted that 
these are an order of magnitude analysis based on the best available numbers from published 
literature. While the mass balance does not close because of unknown rates of production, 
exact cell densities, and exact media densities, the cell balance does close; this can be seen in 
Table 3: Cell Balance. The cell balance closes around the system and around each bio-reactor 
within the system.   
The assumed values behind the mass balance with all included values can be found in Appendix 
A. 
After Figure 3: Process Flow Diagram for Stem Cell Facility, a top down layout of the facility has 
been provided in Figure 4: Clean Room Top Down Layout to help understand positioning within 
the clean room. All manufacturing equipment is included and to scale. 
Energy calculations were done in order to determine the amount of electricity required for 
utility costing. These calculations can be found in Appendix A: Energy Calculations. 
 
                                                          
16
 (Technologies, 2011) 
17
 (Kielberg, 2010) 
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Table 2: Stream Summary Table 
 
 
Table 3: Cell Balance 
 
 
Table 4: Media Mass Balance 
 
 
Table 5: Cell Mass Balance 
Stream 1 2 3 4 5 6 7 8 9 10 11 12
Number of Cells 1.00E+05 1.00E+05 1.52E+06 2.28E+07 1.49E+08 1.23E+09 9.80E+08 1.96E+09 1.57E+09 2.98E+09 2.98E+09 2.98E+09
Temperature (°C) -130 37 37 37 37 37 37 37 37 37 -50 -195
Cell Mass (g) 0.0001 0.0001 0.00152 0.0228 0.149 1.23 0.98 1.96 1.57 2.98 2.98 2.98
Media volume (mL) 1 N/A N/A N/A N/A N/A N/A N/A N/A 2 2 2
Heat Capacity (J/K) 3.99 0.00 0.00 0.02 0.16 1.29 1.03 2.06 1.65 11.11 11.11 11.11
Stream Transfer 1 to 2 2 to 3 3 to 4 4 to 5 5 to 6 6 to 7 7 to 8 8 to 9 9 to 10 10 to 11 11 to 12
Time Growing - 7.5 7.47 4.57 4.66 - 6 - 6 - -
Cells Grown - 1500000 22480000 152200000 1.076E+09 - 9.8E+08 - 1.57E+09 - -
Cells Lost - 80000 1200000 26250000 245000000 - 3.92E+08 - 1.57E+08 - -
Location Container volume (mL) Media volume added (mL/batch) Media mass added (g/batch) Glucose consumed (g/batch) Glutamine consumed (g/batch) Lactate produced (g/batch) Ammonium produced (g/batch) Sum of metabolites (g/batch) Mass of media removed (g/batch)
Well plate 1 2 17.0 17.3 0.00 0.00 0.00 0.00 0.00 17.3
Well plate 2 30 254 259 -0.02 0.00 0.00 0.00 -0.02 259
Bioreactor 1 50 279 284 -0.09 -0.01 0.01 0.00 -0.09 284
Bioreactor 2 350 1982 2021 -0.66 -0.06 0.06 0.01 -0.65 2021
Rosette Formation 4000 28000 28560 -2.75 -0.25 0.25 0.03 -2.72 28557
Rosette Dissolution 5000 35000 35700 -4.41 -0.40 0.40 0.05 -4.36 35696
Location Biomass Produced (g/batch) Number of cells produced Calculated cell mass (g/batch) Difference % Difference
Well plate 1 1.42E-03 1.50E+06 1.50E-03 -8.35E-05 -5.89%
Well plate 2 2.12E-02 2.25E+07 2.25E-02 -1.25E-03 -5.89%
Bioreactor 1 9.21E-02 1.52E+08 1.52E-01 -6.01E-02 -65.24%
Bioreactor 2 6.51E-01 1.08E+09 1.08E+00 -4.25E-01 -65.36%
Rosette Formation 2.72E+00 9.80E+08 9.80E-01 1.74E+00 64.02%
Rosette Dissolution 4.36E+00 1.57E+09 1.57E+00 2.79E+00 64.02%


























































































































Figure 3: Process Flow Diagram for Stem Cell Facility 
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Figure 4: Clean Room Top Down Layout 
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Technical Issues and Design Practices 
Key Assumptions 
Several assumptions were made in this design project. These are outlined below and were used 
for calculations unless otherwise stated.  
Cells: 
1. The beginning amount of cells is 1 X 105 cells/batch 
2. The beginning cells are induced pluripotent stem cells 
3. The minimum cell density for seeding a well plate is 5 X 104 cells/mL18 
4. The maximum cell density for a well plate is 8 x 105 cells/mL* 
5. The minimum cell density for seeding a reactor is 1.25 X 105 cells/mL* 
6. The maximum cell density for a reactor is 3.5 X 106 cells/mL* 
7. The doubling time for two dimensional growth (well plates) of iPSCs is 33 hours* 
8. The doubling time for three dimensional growth (microcarriers) is 21 hours* 
9. The doubling time for NPCs is 96 hours19 
10. The needed cell density for a single treatment is 2 X 107 cells20 
11. There is a two day lag time for cells to adjust to their environment and attach to the 
growing area21 
12. The differentiation time for iPSCs to NPCs is 12 days22 
13. The mass of a cell is 1 ng23 
14. The density of a cell is 1.05 g/mL   
Reactors: 
1. 80% daily replacement of media in each system in the bioreactor train to ensure proper 
nutrition and pH conditions for cells*  
2. No losses from beginning vial to first well plate (WP-1) 
3. Losses from WP-1 to second well plate (WP-2) are 5% to account for non-viability 
4. Losses from WP-2 to the spinner reactor (BR-1) are 5% to account for non-viability 
5. Losses from BR-1 to the second bioreactor (BR-2) are 15% to account for non-viability 
and incomplete transfer 
6. Losses from BR-2 to the third bioreactor (BR-3) are 20% to account for non-viability, 
incomplete transfer, filtration and cleaving from the microcarriers 
7. Losses from BR-3 phase 1 (neural induction) to BR-3 phase 2 (rosette selection) are 20% 
to account for non-viability, incomplete transfer, and filtration 
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8. Losses from BR-3 phase 2 (rosette selection) and freezing are 5% for non-viability.  
General: 
1. Addition of 8 mg/mL of microcarriers for sufficient cellular growing area24 
2. Microcarriers swell 15 mL/g25 
3. Density and heat capacity of media is comparable to salt water (35 grams of salt / 
kilogram of water)26 
4. The heat capacity of a cell is equivalent to the heat capacity of the human body which is 
3.47 J/g-K27 
Design Procedure 
The following tables are a summary of our equipment. They are followed by descriptions, 
specifications, and design considerations behind each piece of equipment. 
Table 6: Bio-reactor Equipment Summary 
 
Table 7: Heating & Cooling Equipment Summary 
 
Table 8: Auxiliary Equipment Summary 
 
                                                          
24
 (Oh et al., 2009) 
25
 (Sciences, 2011) 
26
 (Laboratory, 2015) 
27
 (Toolbox, 2016) 
Equipment Volume (mL) Temperature (°C) DO (% of air saturation) pH MoC Growth Area (cm2) Attachment Method RPM
WP-1 2 37 30% 6.8-7.4 Plastic 8.8 Coated Matrix N/A
WP-2 30 37 30% 6.8-7.4 Plastic 38.4 Coated Matrix N/A
BR-1 350 37 30% 6.8-7.4 Glass 1080 Microcarriers 60
BR-2 500 37 30% 6.8-7.4 Glass 6480 Microcarriers 60
BR-3 5000 37 4% 6.8-7.4 Glass N/A Supsension 60
Equipment Peak Power (W) Footprint (WxD) Volume (L) Temperature (°C) MoC
F-1 1081 29.3"x24" 326 4 Cold-Rolled Steel
F-2 920 29.3"x24" 326 -20 Cold-Rolled Steel
F-3 2300 25.5"x30.75" 28 -50 Steel with Epoxy Finish
F-4 N/A 22" O.D. 71 -196 Powder Coated Steel
I-1 460 23.5"x18.5" 40 37 Cold-Rolled Steel
A-1 1400 21.5"x20" 19 121 Stainless Steel
Equipment Peak Power (W) Footprint (WxD) Volume (L) MoC
UV-1 180 15.25"x20.5" 97 Stainless Steel
UV-2 105 25.75"x13.5" 316 Polypropylene
C-1 260 17.2"x22.4" .72 or .042 Stainless Steel
WB-1 1032 15.5"x17" 10 Stainless Steel
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This system (WP-1) in the bio-reactor train is a single well plate that is made of polystyrene and 
is manufactured and shipped under sterile conditions. It is coated with an adherent matrix in 
order to provide adequate cell growth area. The two mL volume of the petri dish was 
determined based upon finding the volume required to seed the starting cell amount based on 
seeding density. It has a growth area of 8.8 cm2. The petri dish is kept at 37 °C, under 30% air 
saturation for oxygen content, and a pH of 7.2 to ensure optimal growth conditions. The 
required daily media replacement for this system is 1.6 mL of growth media. This system is not 
agitated. This system is disposable. 
WP-2: 
This system (WP-2) in the bio-reactor train is a 6-well plate tray that is made of polystyrene and 
is manufactured and shipped under sterile conditions. It is coated with an adherent matrix in 
order to provide adequate cell growth area. The 30 mL volume of the 6-well plate tray was 
determined based upon finding the volume required to seed the starting cell amount based on 
seeding density.  It has a growth area of 38.4 cm2. The 6-well plate tray is kept at 37°C, under 
30% air saturation for oxygen content, and a pH of 7.2 to ensure optimal growth conditions. 
The required daily media replacement for this system is 24 mL of growth media. This system is 
not agitated. This system is disposable. 
BR-1: 
This system (BR-1) in the bio-reactor train is a 100 mL spinner flask that is made out of glass and 
is manufactured and shipped under non-sterile conditions. Therefore, the spinner flask must be 
cleaned upon arrival. Cells grow on microcarriers added to the system which provide 1,080 cm2 
of growing area to the cells. The spinner flask is kept at 37 °C, under 30% air saturation for 
oxygen content, and a pH of 7.2 to ensure optimal growth conditions. The bio-reactor will be 
maintained under a 5% CO2 atmosphere. This system is agitated by a magnetic stirrer. The rate 
of agitation will be manipulated to control the dissolved oxygen set point. The required daily 
media replacement for this system is 40 mL of growth media as the working volume of this 
reactor is 50 mL. This system is not disposable and it will require cleaning after each use before 
it may return to service. 
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BR-2: 
This system (BR-2) in the bio-reactor train is a 500 mL reactor that is made out of glass and is 
manufactured and shipped under non-sterile conditions. Therefore, it will also require cleaning 
upon arrival to the facility. Cells grow on microcarriers added to the system which provide 
6,480 cm2 of growing area to the cells. The bio-reactor will be maintained under a 5% CO2 
atmosphere. The reactor is kept at 37 °C, under 30% air saturation for oxygen content, and a pH 
of 7.2 to ensure optimal growth conditions. This system is agitated by an impeller on the inside 
of the reactor tank. The rate of agitation will be manipulated to control the dissolved oxygen 
set point. The required daily media replacement for this system is 280 mL of growth media as 
the working volume of this reactor is only 350 mL. This system is not disposable and it will 
require cleaning after each use before it may return to service. 
BR-3 
This system (BR-3) in the bio-reactor train is a 5000 mL (5 L) reactor that is made out of glass 
and is manufactured and shipped under non-sterile conditions. Therefore, it like BR-2 and BR-1 
will require cleaning upon arrival to the facility. No microcarriers are used in this reactor as the 
cells in this step form rosettes to induce differentiation. The bio-reactor will be maintained 
under a 5% CO2 atmosphere. The reactor is kept at 37 °C, under 4% air saturation for oxygen 
content, and a pH of 7.2 to ensure optimal growth conditions. This system is agitated by an 
impeller on the inside of the reactor tank. The rate of agitation will be manipulated to control 
the dissolved oxygen set point. As explained above in the process description section this 
reactor is used twice. The first time it is used the daily media replacement for the system is 
3,200 mL of neural induction media as it has a working volume of 4,000 mL (4 L). The second 
time it is used the daily media replacement for the system is 4,000 mL (4 L) of rosette selection 
media as it has a working volume of 5,000 mL (5 L).  As this system is not disposable, it will 
require cleaning after each use before it may return to service. The cleaning of this system is 
critical and must be done efficiently as it will have the quickest turnaround time of any other 
step in this process as can be seen in Figure 2: High Production Gantt Chart 
F-1: 
This is a refrigerator that is capable of operating between 2 °C and 8 °C. It operates at 4 °C and 
contains parts of the growth media and the freezing preparation media. This refrigerator is 
sized so that it will be able to contain enough media to complete 12 batches should media 
shipments be disrupted. This will run four reactor trains for approximately three weeks. 
F-2: 
This is a freezer that is capable of operating between -20 °C and -30 °C and is held at -20 °C. It 
contains parts of the growth media and the neural induction media. This freezer is sized so that 
it will be able to contain enough media to complete 12 batches should media shipments be 
disrupted. This will run four reactor trains for approximately three weeks. 
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F-3: 
This deep freezer is capable of operating between -50 °C and -80 °C and is held at -50 °C. 
Purified NPCs are placed within a temperature regulating cooling apparatus and subsequently 
placed within this freezer to cool from room temperature down to -50 °C. 
F-4: 
This is a liquid nitrogen freezer. It is used for the final cooling of purified NPCs and storage 
before shipment. It operates at -196 °C. This was designed to ensure that the packaged 
treatments did not have any biological activity, which stops at temperatures below -130 °C28. 
I-1: 
The incubator is used to regulate the temperature of the well plates. It is set at 37 °C and 
operates year around. It has a 5% CO2 atmosphere and 95% humidity to prevent the media 
from evaporating. 
A-1: 
This is the autoclave that is used to neutralize liquid wastes such as expended daily media. It is 
19 L and is able to hold and entire batch’s worth of media should contamination of that batch 
occur. It operates at 121 °C for 30 minutes to sterilize the waste. 
UV-1: 
This is the in-lab UV cabinet. It is used to sterilize neural induction media. It is also used to 
sterilize any potential solid biohazards before disposal. 
UV-2: 
This is the UV cabinet in the changing room that can be used to sterilize materials that cannot 
be soaked in ethanol but need to be brought into the clean room.  
C-1: 
This is the centrifuge. It is sized to fit at most four 180 mL centrifuge tubes and has  a 
replaceable rotor in order to be used for smaller vial sizes such as when centrifuging vials 
during vial thaw. It is capable of holding 36 2 mL vials. 
WB-1: 
This is the water bath. It holds 10 L of water and is used to preheat media to 37 °C and thaw 
cells. 
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H-1: 
This is a laminar flow fume hood. It is used in several protocols in order to maintain aseptic 
technique when handling cells. 
QC-1: 
This is the cell counter used for quality control. It has the ability to count the total amount of 
cells in a sample as well as the non-viable amount of cells in a sample. These two numbers 
allow for the determination by difference of the total viable cell count per sample. 
QC-2: 
This is the cell analyzer used for quality control. It is a polymerase chain reaction (PCR) system 
that analyzes the RNA of the cells for specific gene expressions for positive identification of the 
cellular make-up when compared to a known standard. 
Health & Safety 
 
This facility was designed with consideration for the safety of the facility personnel and health 
of the future patients in each step of the design process. When looking at the hazards present 
in this facility they are significantly more nuanced than the majority of hazards that would be 
found in a refinery, chemical plant, or off-shore drilling rig. This makes a proper hazard analysis 
as well as appropriate consideration to contamination pathways paramount to the successful 
operation of the facility.  
One could understand the temptation that exists to assume that since the hazards in this facility 
are unassuming and that the product is meant to be used in medicine that its production is 
benign. This however is most certainly not the case. The following section of this report will 
cover; proper manufacturing practices for the facility, identified hazards to the safety of plant 
personnel, potential contamination pathways that would jeopardize the safety of patients, the 
consequence of these occurrences, and steps that were taken to provide an inherently safe 
design with an appropriate amount of safeguards.       
Current Good Manufacturing Practice (cGMP) 
 
This facility was designed to meet the standards of current good manufacturing practice 
(cGMP) laid out by the United States Food and Drug Administration (FDA) which is charged with 
ensuring safe products and treatments are provided to the American Public. Notice that this 
facility is compliant with United States federal regulations and that upon determination of the 
location of the facility further investigation should be done to ensure state and local regulations 
are met. Different regulatory environments will exist outside of the United States and proper 
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consideration to these requirements should occur if the decision to open a facility outside of 
the United States is made. 
The design criterion explicitly states that the facility needs to be cGMP compliant. However, 
when looking at the FDA’s regulations the closest category that this facility fit would be a 
“Phase 1 Investigational Drug”. Looking closer at the industry guidance for this category it is 
revealed that “this guidance does not apply to the following phase 1 investigational products: 
Human cell or tissue products regulated solely under § 361 of the Public Health Service Act”29. 
Occasionally there are requirements that cGMP does not sufficiently cover in the required 
procedures to meet federal regulation. Therefore, pursuant to § 361 of the Public Health 
Service Act this facility must follow current good tissue practice (cGTP) to ensure that it is 
always in compliance with federal regulation30. In more simple terms, because this facility 
produces human cells for use in cell therapies it must follow the more stringent requirement of 
cGTP which will also satisfy good cGMP requirements.  
After reading the Industry Guidance for “Current Good Tissue Practice (CGTP) and Additional 
Requirements for Manufactures of Human Cells, Tissues, and Cellular and Tissue-Based 
Products (HCT/Ps)” compiled by the FDA the following design considerations were made to 
ensure proper manufacturing of stem cells from this facility. This design meets the core cGTP 
requirements as outlined below. 
All of the manufacturing steps occur in a 25 ft. by 36 ft. (900 ft2) ISO Class 3 clean room. The 
clean room is outfitted such that it has controls for temperature and humidity, adequate 
ventilation and air filtration, and is able to maintain conditions that allow for equipment to 
operate in an aseptic process. The facility is cleaned using 70% ethanol for intentional 
decontamination of new materials entering the clean room. Employees are provided with an 
antechamber to change into lab clothes before entering the clean room proper.  
While the majority of the manufacturing process occurs in the main section of the clean room, 
mix-ups of cells will be prevented with procedures and the volume differences inherent at the 
different steps. Furthermore, the storage location for cells ready to be picked up is a separate 
section from the rest of the clean room. 
All purchased equipment will meet qualification requirements and be of a design that limits the 
chances of contaminating any of the samples. All protocols will follow the manufacturer’s 
procedures for proper usage. Equipment will be properly maintained and regularly inspected 
and calibrated. 
All supplies and reagents, unless otherwise stated, used in this process will be purchased from 
manufactures that provide sterile non-human based products for the facility. A major exception 
                                                          
29
 (United States, 2008) 
30
 (United States, 2011) 
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to this is the neural induction media which will come from human-feeders and thus will be 
irradiated in UV-1 in order to inactive any potential virus before being used in the process31. 
No recovery is expected to occur within the facility as the cells required to start the process are 
shipped in a sterile condition to the facility. This design is not prepared to handle recovery 
operations and as a result no recovery operations should occur within the facility.  
It is not expected that this facility will encounter dura mater or transmissible spongiform 
encephalopathy (TSE). While the facility does deal with developing cells for treatment in spinal 
injuries, the cells provided from donors that initiate each process are iPSCs that could have 
been acquired from almost anywhere in the donor’s body. It is assumed that the cells were not 
acquired from the donor’s spinal cord or brain. Lastly, NPCs are not known to differentiate into 
dura mater. 
Testing of the cells manufactured in this facility occurs at the end of the expansion phase, which 
occurs after BR-2, and at the end of the differentiation phase, which occurs after the second 
instance of the cells in BR-3. The quality control tests and protocol can be further read about in 
the section of this report called “Other Important Considerations.” 
Labeling practices of the facility will follow the industry standard and insure that the labels are 
accurate, legible and maintain the integrity of the label. 
Storage facilities on-site will be independently temperature controlled from the clean room and 
proper labeling will ensure that expired material is discarded so as to not enter the 
manufacturing process. 
Disposal of wastes from this facility occurs in one of two ways dependent upon if the waste is a 
liquid or solid. Liquid wastes, such as the daily expended media, are placed within a 19 L 
Autoclave kill tank (A-1) and heated to 121°C for 30 minutes in order to ensure all biological 
wastes are destroyed. The pH of the solution is checked with litmus paper to ensure that the 
solution has a pH between 5 and 9. The solution is anticipated to be near neutral but 
hydrochloric acid and sodium hydroxide are on-site for any necessary neutralization. After 
autoclaving and neutralization the solution is poured down the sink to the sewer system. Solid 
wastes are soaked in 70% ethanol for 30 minutes before being discarded. Alternatively, some 
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Of the chemicals found within the facility the majority are of proprietary blend and therefore 
only list material properties if they are dangerous. None of the media had dangers listed. 
Outside the media, Table 10: Material Properties contains material properties of chemicals of 
interest. 





The provided interaction matrix seen below contains the majority of the chemical components that are 
anticipated to be in the facility. Exact make-up of the different media is unknown, but Phosphate Buffer 
Saline was used as a close approximation of what can be expected. There appears to be several 
concerning reactions, however it was determined that the program is assuming that sizeable quantities 
of solid material would be available to react. This is not the case for this facility as these chemicals are 
dissolved and not expected to have significant interactions with their surroundings. This interaction 
matrix was developed using the NOAA software and CRW3 program. 
 
Figure 5: Interaction Matrix 
 
Material Properties MW (g/mol) Boiling Point (°C) Liquid Density (kg/L) Reactivity With Water Toxicity Limits
Water 18.01 100.00 1 n/a >90 (ml/kg)
Carbon Dioxide 44.01 -78.50 n/a n/a non-toxic
Liquid Nitrogen 28.01 -196.00 0.807 n/a non-toxic
Sodium Bicarbonate 84.01 n/a 2.159 n/a >3360 (mg/kg)
Hydrochloric Acid (20%) 36.46 108.58 1.2 yes 900 (mg/kg)
Sodium Hydroxide 40.00 1388.00 2.13 yes >500 (mg/kg)
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Safety Assessment Results 
Hazard Identification & Potential Consequence Summary 
 
Table 11: Hazard & Potential Consequence Summary 
 
 
Table 11: Hazard & Potential Consequence Summary contains several hazards that were identified 
in the process along with the potential consequences of those hazards. 
Hazard 1 is if a virus were to make it through the facility and into a treatment that was then 
used during surgery and led to a patient suffering harm in some fashion. This would have little 
impact on the equipment or process but would be disastrous economically and legally. 
Hazards 2, 3, and 4 are all contamination pathways that would lead to the contaminated batch 
being destroyed when it was determined to be contaminated by quality control. 
Hazard 5 assumes that a gas cylinder under pressure is not secured and begins to discharge. 
This could cause serious damage to the equipment and disrupt the process potentially leading 
to large economic losses. 
Hazards 6 and 7 could result in potential equipment damage. 
Hazard 8 occurs when a technician becomes complacent in the workplace and potential 
damage to equipment or contamination could occur should the technician stop following the 
proper protocols. 
Hazard 9 would be just as impactful as Hazard 1 and would lead to great economic loss and 
legal trouble.  
Hazards 10, 11 and 12 are all potential hazards that would ruin a batch of cells and are 




Hazard No. Hazard Equipment Damage Process Disruption Economic Impact Legal/PR
1 Virus in Treatment - - high high
2 Contamination Pathway: Non-Aseptic Technique - high medium/low -
3 Clean Room Breach low high high -
4 Tainted Media - high medium/low -
5 Unsecured Gas Cylinder high high high -
6 Liquid Nitrogen Spill low medium high/medium -
7 HCl/NaOH Spill low low - -
8 Technician Inattention high high high/medium -
9 QC Failure - - high high
10 Improper Differentiation - high medium/low -
11 Incorrect Media - high/medium high/medium -
12 Improper Biohazard Disposal - - low medium




Table 12: Inherently Safer Design Application Summary 
 
Table 12: Inherently Safer Design Application Summary shows which hazards have been 
systematically mitigated by the design of this facility. It focuses on minimizing hazardous 
material being used and proper procedures being followed.  
 
Table 13: Opportunities for Additional Design Safeguards 
 
Table 13: Opportunities for Additional Design Safeguards addresses the hazards that need to be 
evaluated in detailed design. The majority of these safety recommendations center on proper 
training of the technicians as well as protocol being followed.  
Inherent Safety Design Summary 
 
The result of the hazard analysis indicates that there are some potentially catastrophic events 
such as virus infection of a patient or quality control failure. These hazards have been reduced 
through an inherently safe design but can further mitigated through procedures and training 
established in detailed design. None of these hazards present potential for project termination. 
The only major concern that requires special attention is maintaining the sterility of the clean 
room and manufacturing process. Overall, this process does not pose immediate risk to those 
involved in the day-to-day operation of the facility and is a safe operation. 
Economic Analysis 
 
Hazard No. Hazard Inherient Safety/User Friendly  Concept Incorperation
1 Virus in Treatment Procedure QC tests
Limitation of Effects Batch Disposal
Avoiding Domino Effect Multiple Reaction Trains
4 Contamination Pathway Tainted Media Procedure UV Sterilization
6 Liquid Nitrogen Spill Minimization Limited Liqid Nitrogen Usage
Limitation of Effects Separated Liquid Nitrogen Area
7 HCl/NaOH Spill Minimization Limited Need for HCl/NaOH
10 Improper Differentiation Procedure Filtering Rosettes
12 Improper Biohazard Disposal Procedure UV and Autoclave Sterilization
Hazard No. Hazard Considerations
2 Contamination Pathway: Non-Aseptic Technique Aseptic Training and Procedure
3 Clean Room Breach Clean Room Training and Disinfection Protocol
5 Unsecured Gas Cylinder Secure Gas Cylinders
8 Technician Inattention Training and Monitoring
9 QC Failure QC Training and Procedures
11 Incorrect Media Proper Labeling and Storage System
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The standalone assumption has been made for economic analysis of the project. This is because 
the company is a small to midsized company with an absence of other projects that may have 
produced other taxable revenue that could be reduced by losses incurred from this project. 
Beyond the operational difficulties of handling large volumes and maintaining thermal and 
nutrient ubiquity throughout large reactors with low mixing speeds there exists economic 
rationale for limiting reactor size. The economic rationale is to limit volume levels in order to 
mitigate the economic losses and business disruption that occurs should a batch become 
contaminated. This is achieved by limiting reactor volume and meeting production 
requirements with reduced downtime between batches and multiple reactor trains. 
The module system and the ability to mix and match reactor train totals and production rates 
allows for cell production levels to respond to market forces. The initial capital investment will 
allow for the creation of the first module with a single reactor train. While the price per 
treatment of this set-up will be higher than if all four reactor trains were being used, it allows 
for initial treatments and production to occur in order to prove the viability of this cell therapy 
to the broader market. As demand for cell production increases more reactor trains can be 
added to the module. Since the internal rate of return (IRR) is fixed at 50% the more treatments 
produced per module the cheaper the treatment can be sold. 
If any of the following events or combination of events occurs: 
a) The original module is unable to meet market demand 
b) A sufficient market demand develops in a location distant from the original module 
c) Regulatory constraints on production, transportation or sale of the treatment in new markets 
Then new modules can be produced in those areas to address the events as they occur. The 
above list of events is simply speculation on the most likely explanations for the addition of 
another module and should not be considered exhaustive. 
There are many ways to operate this facility and the economic analysis covers three different 
scenarios. The first scenario is a single module operating with one reactor train at low 
production. The second scenario is a single module operating with one reactor train at high 
production. The third and final scenario is a single module operating with four reactor trains at 
high production. Any combination between scenario one and three should be acceptable. An 
economic analysis was not provided for all possible scenarios as the expected economic 
outcome will fall between the economics of the first and third scenarios. 
Table 14: Economic Analysis Summary 
 
Production Type Annual Treaments Treatment Price Percent Price Reduction
Scenario 1 Low Production, 1 Train 1,485 2,466$                                           -
Scenario 2 High Production, 1 Train 4,471 1,005$                                           59%
Scenario 3 High Production, 4 Train 17,882 508$                                               79%
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Table 14: Economic Analysis Summary provides a simple direct comparison of the different 
scenario production outcomes. It proves the annual treatments produced the cost that each 
treatment would need to be sold in order to achieve a 50% IRR and how much cheaper the 
treatment gets with increased production. 
Capital Cost Estimates 
 
Due to the unique scope of the project, the capital cost estimates are based on current prices 
for equipment that is similar to what is needed to operate the manufacturing facility. The 
selected equipment meets all the specifications needed for the process, but is as small as is 
feasible in order to minimize the size of the clean room. The clean room and all non-disposable 
equipment that the cells or the media need in order to be processed is included in the capital 
cost estimates. All prices obtained are current prices, and since equipment for the 
manufacturing facility will be purchased this year in order to prepare for operation next year, 
the prices were not escalated. 
Since the equipment is not large or complex, and all equipment used for reference had set up 
and operation guides, it was assumed that the technicians hired are able to properly set up the 
equipment. Therefore, no cost was added for installation cost. However, to cover any fees 
associated with purchasing or shipping a cost of 3% was added to the base purchase price of 
the equipment. To cover any contingencies in purchasing or delivering the equipment 15% was 
added to the base purchase price.  
Capital costs are split into two categories: module equipment and reactor train equipment. 
Module equipment is any equipment that is only purchased for a new module and will be used 
regardless of how many reactor trains are operating. Reactor train equipment consists of all 
equipment that must be purchased for each reactor train that is operating in the module as 
each reaction train needs a unique set of equipment to operate efficiently. 
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Table 15: Fixed Capital Investment per Module 
 
Table 16: Fixed Capital Investment per Reactor Train 
 
Table 15: Fixed Capital Investment per Module above lists the estimated price for the capital costs 
along with the total cost after contingencies and fees for the module equipment. While Table 
16: Fixed Capital Investment per Reactor Train above lists the estimated price for the capital costs 
for the reactor train equipment. The final investment for both the single train and four train 
systems are totaled at the bottom of the Table 16: Fixed Capital Investment per Reactor Train and 
are referred to as the fixed capital investment (FCI) in the rest of the report. 
Item Price Price with Contengencies and Fees
Clean Room 729,000$                    860,220$                                                      
UV Sterilizer (UV-1) 1,152$                         1,359$                                                          
UV Cabinet (UV-2) 4,602$                         5,430$                                                          
Liquid Nitrogen Freezer (F-4) 6,095$                         7,192$                                                          
Deep Freezer (F-3) 10,406$                      12,279$                                                        
Freezer (F-2) 7,292$                         8,605$                                                          
Refrigerator (F-1) 5,559$                         6,559$                                                          
Laminar Flow Hood (H-1) 8,349$                         9,852$                                                          
Autoclave (A-1) 5,760$                         6,797$                                                          
Large Centerfuge (C-1) 1,395$                         1,646$                                                          
Water Bath (WB-1) 467$                            551$                                                              
Incubater (I-1) 5,322$                         6,280$                                                          
Cell Counter (QC-1) 15,000$                      17,700$                                                        
Cell Analyzer (QC-2) 30,900$                      36,462$                                                        
Total FCI/Module 980,932$                                                      
Item Price Amount Needed Total Total with Contengencies and Fees
Bio-reactor 1 w/ pH 1,152.44$                   1 1,152.44$                     1,359.88$                                                    
Bio-reactor 2 (BR-2) 21,942.68$                1 21,942.68$                   25,892.36$                                                  
Bio-reactor 3 (BR-3) 52,094.24$                1 52,094.24$                   61,471.20$                                                  
Cooling Containers 106.00$                      9 954.00$                         1,125.72$                                                    
Total FCI/Train 89,849.16$                                                  
Total FCI for 1 Train 1,070,781.37$                                            
Total FCI for 4 Trains 1,340,328.87$                                            
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Figure 6: Bio-reactor Price Correlation 
The bio-reactor price was determined from the provided economics spreadsheet from GE by 
modeling the prices as a function of volume. A correlation was established, as seen in Figure 6: 
Bio-reactor Price Correlation, and used to estimate the cost of a 5 L and a 0.5 L reactor as they 
were not offered as sizes on the spreadsheet. The calculated prices are shown in Table 16: Fixed 
Capital Investment per Reactor Train. 
Manufacturing Cost Estimates 
 
The manufacturing costs for this facility were determined on a per batch basis and a per 
module basis. This was done because increasing production rates only reduces downtime it 
does not change the total cost to produce any individual batch. More simply put, operating at 
low production rates provides 10 batches per year and at high production rates is 30 batches 
per year, regardless of how many batches are produced that year the manufacturing costs to 
produce that batch are unchanged. There are still some costs that are incurred for simply 
operating a module regardless of how many batches are produced from that module. In order 
to calculate the price per year for batch costs one must simply multiple the total batch cost by 
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Table 17: Raw Material Costs per Module 
 
The raw material costs per batch can be seen in Table 17: Raw Material Costs per Module. This 
includes the initial vial of cells and all media required for the expansion, differentiation, and 
storage of the cells. 
Table 18: Operating Cost per Batch 
 
The operating costs per batch can be seen in Table 18: Operating Cost per Batch. This includes the 
disposable materials such as the well plates, microcarriers, chemicals and intermediate cell 
holders. The prices have been left unrounded to the penny, as rounding of this table would 
cause significant distortion to the table. 
Item  Price/batch 
Adult Stem Cells $587
Growth Media $1,338
Neural Induction Media $19,118
Rosette Selection Media $10,150
Cryopreservation Media $607
Total $31,799
Raw Materials Per Batch
Item Price/batch
TrypLE 58.22$            
Microcarriers 11.94$            
Microcarrier Prep 52.92$            
Well Plate 1 0.80$              
Well Plate 2 11.94$            
40 Micron Cell Strainer 33.28$            
100 Micron Cell Strainer 33.28$            
400 Micron Cell Strainer 33.28$            
50 mL Centerfuge Tubes 11.36$            
Cryovials 105.85$          
Cryocontainers 0.31$              
NucleoCassettes 14.80$            
Reagent A100 0.07$              
Reagent B100 0.07$              
QC Growth Wellplate 568.00$          
QC Differentiation Wellplate 568.00$          
RNA Kit 46.80$            
Ethanol 54.96$            
Total 1,605.89$      
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Table 19: Operating Cost per Module 
 
The operating costs per module can be seen in Table 19: Operating Cost per Module. These costs 
are incurred when a single batch is run and are mostly independent of the production rate of 
the facility. These costs contain an estimation of the total disposables used to operate a 
laboratory and should be sufficient to cover all of the production rates32. 
Table 20: Utility Cost Per Batch 
 
The utility costs per batch can be seen in Table 20: Utility Cost Per Batch. This includes the 
electricity to operate all equipment and water consumption. 
                                                          
32
 (Veronese, 2011) 
Item Cost/Year
CO2 30$                
Liquid Nitrogen 369$             
Disposables 20,000$       
Total 20,399$       
Electricity Usage Power (kW) Hours/Batch Cost/Batch
Bio-reactor 1 (BR-1) 1.05 180.00 9.45$                                                          
Bio-reactor 2 (BR-2) 0.418 179.28 3.75$                                                          
Bio-reactor 3 (BR-3) 0.418 288.00 6.02$                                                          
Autoclave (A-1) 1.4 1.50 0.11$                                                          
Centerfuge (C-1) 0.26 0.03 0.00043$                                                   
Cell Counter (QC-1) 0.01 2.40 0.0012$                                                     
Cell Analyzer (QC-2) 0.025 0.03 0.00004$                                                   
Water Bath (WB-1) 1.032 2.13 2.19$                                                          
Water Volume (L)
Rinsing Water 9.85 9.85$                                                          
Autoclave (A-1 Water Consumption) 1.65 1.65$                                                          
Total 33.02$                                                       
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Table 21: Utility Costs per Module 
 
The utility costs per module can be seen in Table 21: Utility Costs per Module. This shows the 
utility costs that are incurred by simply operating the module and these costs are independent 
of production rates. 
Table 22: Waste Treatment Costs 
 
The waste treatment cost per batch and per module is provided in Table 22: Waste Treatment 
Costs. 
Table 23: Labor Cost Summary 
 
Electricity Usage Power (kW) Hours/Batch Cost/year
Fume Hood 0.261 8760 114.32$                                                     
Incubater 0.46 8760 201.48$                                                     
Refrigerator 1.081 2920 157.83$                                                     
Freezer 0.92 2920 134.32$                                                     
Deep Freezer 2.3 2920 335.80$                                                     
UV Irradiator 0.18 1073.1 9.66$                                                          
UV Cabinet 0.105 8760 45.99$                                                       
Water Bath Heating Water 1.032 141.255 7.29$                                                          
Cell Counter Standby 0.000002 8760 0.00088$                                                   
Water Volume (L) Cost/year
Water Bath 3650 1.98$                                                          
Water for Injection Volume (L) Cost/year
Incubater 295.23 295.23$                                                     
Total 1,303.89$                                                 
Waste Treatment Cost per Batch
Sewage Volume (L) Cost/Batch
Rinsing Water 9.85 0.01$                                                          
Media After Autoclave 55.4368 0.07$                                                          
Water for Autoclave 1.65 0.002$                                                       
Total 0.09$                                                          
Waste Treatment Cost per Module
Sewage Volume (L) Cost/year
Water Bath 3650 4.83$                                                          
Total 4.83$                                                          
Required Workers/Shift Number of People Hired Salary/Year Total cost/Year
Technicians 2 9 41,290.00$ 371,610.00$     
Scientists 1 5 79,930.00$ 399,650.00$     
771,260.00$     
Additional Technician 1 5 41,290.00$ 206,450.00$     
977,710.00$     
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The labor costs were evaluated via data provided by the Bureau of Labor Statistics33,34. It was 
determined that each shift would require at least 2 technicians and 1 medical scientist. An 
additional technician is added when the number of trains in the module is three or four. The 
number of people hired to cover each shift is taken from Turton and assumes that the facility 
operates 24 hours a day35.   
Table 24: Total Manufacturing Costs without Depreciation 
 
Using the method described by Turton, the total cost of manufacturing was calculated for the 
three different scenarios36. This can be seen Table 24: Total Manufacturing Costs without 
Depreciation. 
Table 25: Batch Summary per Year 
 
                                                          
33
 (Statistics, 2014a) 
34
 (Statistics, 2014b) 
35
 (Turton, Bailie, Whiting, & Shaeiwitz, 2009) 
36
 (Turton et al., 2009) 
Direct Manufacturing Costs Scenario 1 Scenario 2 Scenario 3
Production Type Low Production, 1 Train High Production, 1 Train High Production, 4 Train Estimation Factor
Raw Material Cost/Year, CRM 319,131$                             960,561$                              3,842,246$                            n/a
Waste Treatment Cost/Year, CWT 6$                                          8$                                           16$                                          n/a
Utilities Cost/Year, CUT 1,635$                                  2,301$                                   5,293$                                    n/a
Operating Labor, COL 771,260$                             771,260$                              977,710$                               n/a
Direct Supervisory and Clerical Labor 138,827$                             138,827$                              175,988$                               0.18COL
Maintainance and Repairs 64,247$                                64,247$                                 80,420$                                  0.06FCI
Operating Supplies 36,515$                                68,908$                                 214,435$                               n/a
Laboratory Charges 77,126$                                77,126$                                 97,771$                                  Low Estimate 0.1COL
Patents and Royalties 80,510$                                105,491$                              235,643$                               .03*COMd
Total Direct Manufacturing Costs 1,408,747$                          2,083,238$                           5,393,878$                            
Fixed Manufaturing Costs
Local Taxes and Insurance 34,265$                                34,265$                                 42,891$                                  0.032FCI
Lab Overhead Costs 584,600$                             584,600$                              740,471$                               0.708COL+0.036FCI
Total Fixed Manufacturing Costs 618,865$                             618,865$                              783,361$                               
General Manufacturing Expenses
Administration Costs 146,150$                             146,150$                              185,118$                               0.177COL+0.009FCI
Distribution and Selling Costs 295,202$                             386,800$                              864,024$                               .11*COMd
Research and Development 134,183$                             175,818$                              392,738$                               .05*COMd
Total General Manufacturing Costs 146,150$                             146,150$                              185,118$                               
Total Costs 2,173,762$                          2,848,253$                           6,362,357$                            
COMd 2,683,657$                          3,516,362$                           7,854,761$                            Total Costs/.81
Production Type Annual Treaments Batches/Year
Scenario 1 Low Production, 1 Train 1,485 10.04
Scenario 2 High Production, 1 Train 4,471 30.21
Scenario 3 High Production, 4 Train 17,882 120.83
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Lastly, Table 25: Batch Summary per Year contains a summary of the different proposed 
operational production rates. It compares Scenarios 1, 2 and 3.  
Treatment Price 
 
Since the IRR is fixed, the treatment price varies with the total cell production. As production is 
increased and the fixed capital cost remains unchanged more cells are produced at a 
disproportionately cheaper price. This causes the price per treatment to decrease drastically. 
This can be seen in the cash flow sheets for Scenario 1 in Table 26: Cash Flow Sheet for Scenario 1, 
Scenario 2 in Table 27: Cash Flow Sheet for Scenario 2, and Scenario 3 in Table 28: Cash Flow Sheet 
for Scenario 3. 




Minimum rate of return, i* = 0.1 or 10.0%
Other relevant project info.
1 = $1
End of Year 2016 2017 2018 2019 2020 2021 2022 2023
Number of treatments 743                     1,485               1,485               1,485               1,485               1,485               1,485               
 x Sales Price, $/treatment 2,466                  2,466               2,466               2,466               2,466               2,466               2,466               
Net Revenue -                        1,831,188         3,662,377       3,662,377       3,662,377       3,662,377       3,662,377       3,662,377       
 - Cost of Manufacturing (1,341,828)        (2,683,657)     (2,683,657)     (2,683,657)     (2,683,657)     (2,683,657)     (2,683,657)     
 - Depreciation (214,156)           (342,650)         (205,590)         (123,354)         (123,354)         (61,677)           -                        
 - Loss Forward -                        -                        -                        -                        -                        -                        
Taxable Income -                        275,204             636,070          773,130          855,366          855,366          917,043          978,720          
 - Tax @ 40% -                        (110,082)           (254,428)         (309,252)         (342,146)         (342,146)         (366,817)         (391,488)         
Net Income -                        165,122             381,642          463,878          513,220          513,220          550,226          587,232          
 + Depreciation -                        214,156             342,650          205,590          123,354          123,354          61,677             -                        
 + Loss Forward -                        -                           -                        -                        -                        -                        -                        -                        
 - Fixed Capital (1,070,781)     -                           -                        -                        -                        -                        -                        -                        
Cash Flow (1,070,781)     379,279             724,292          669,468          636,574          636,574          611,903          587,232          
Discount Factor (P/F i*,n) 1.0000 0.9091 0.8264 0.7513 0.6830 0.6209 0.5645 0.5132
Discounted Cash Flow (1,070,781)     344,799             598,588          502,981          434,788          395,262          345,403          301,343          
NPV @ i* = 1,852,384       
DCFROR = 50%
Paybock Period = 2.25                 years
Low Production of Stem Cell Treatments
5 Year MACRS Depreciation
Stand Alone
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Table 27: Cash Flow Sheet for Scenario 2 
 
Table 28: Cash Flow Sheet for Scenario 3 
 
The project evaluation life was assumed to be 7 years as this gives a reasonable range to 
produce revenue that offsets the initial capital investment. A 5 year MACRS deprecation was 
used as this facility is made up primarily of laboratory and research equipment. In accordance 
with MACRS, the assumption is made that the facility is only in production for half a year for the 
Project Title:
Corporate financial situation:
Minimum rate of return, i* = 0.1 or 10.0%
Other relevant project info.
1 = $1
End of Year 2016 2017 2018 2019 2020 2021 2022 2023
Number of treatments 2,235                  4,471               4,471               4,471               4,471               4,471               4,471               
 x Sales Price, $/treatment 1,005                  1,005               1,005               1,005               1,005               1,005               1,005               
Net Revenue -                        2,247,541         4,495,082       4,495,082       4,495,082       4,495,082       4,495,082       4,495,082       
 - Cost of Manufacturing (1,758,181)        (3,516,362)     (3,516,362)     (3,516,362)     (3,516,362)     (3,516,362)     (3,516,362)     
 - Depreciation (214,156)           (342,650)         (205,590)         (123,354)         (123,354)         (61,677)           -                        
 - Loss Forward -                        -                        -                        -                        -                        -                        
Taxable Income -                        275,204             636,070          773,130          855,366          855,366          917,043          978,720          
 - Tax @ 40% -                        (110,082)           (254,428)         (309,252)         (342,146)         (342,146)         (366,817)         (391,488)         
Net Income -                        165,122             381,642          463,878          513,220          513,220          550,226          587,232          
 + Depreciation -                        214,156             342,650          205,590          123,354          123,354          61,677             -                        
 + Loss Forward -                        -                           -                        -                        -                        -                        -                        -                        
 - Fixed Capital (1,070,781)     -                           -                        -                        -                        -                        -                        -                        
Cash Flow (1,070,781)     379,279             724,292          669,468          636,574          636,574          611,903          587,232          
Discount Factor (P/F i*,n) 1.0000 0.9091 0.8264 0.7513 0.6830 0.6209 0.5645 0.5132
Discounted Cash Flow (1,070,781)     344,799             598,588          502,981          434,788          395,262          345,403          301,343          
NPV @ i* = 1,852,384       
DCFROR = 50%
Paybock Period = 2.25                 years
Stand Alone
One Train High Production of Stem Cell Treatments
5 Year MACRS Depreciation
Project Title:
Corporate financial situation:
Minimum rate of return, i* = 0.1 or 10.0%
Other relevant project info.
1 = $1
End of Year 2016 2017 2018 2019 2020 2021 2022 2023
Number of treatments 8,941                  17,882             17,882             17,882             17,882             17,882             17,882             
 x Sales Price, $/treatment 508                     508                   508                   508                   508                   508                   508                   
Net Revenue -                        4,539,927         9,079,854       9,079,854       9,079,854       9,079,854       9,079,854       9,079,854       
 - Cost of Manufacturing (3,927,381)        (7,854,761)     (7,854,761)     (7,854,761)     (7,854,761)     (7,854,761)     (7,854,761)     
 - Depreciation (268,066)           (428,905)         (257,343)         (154,406)         (154,406)         (77,203)           -                        
 - Loss Forward -                        -                        -                        -                        -                        -                        
Taxable Income -                        344,481             796,188          967,750          1,070,687       1,070,687       1,147,890       1,225,093       
 - Tax @ 40% -                        (137,792)           (318,475)         (387,100)         (428,275)         (428,275)         (459,156)         (490,037)         
Net Income -                        206,688             477,713          580,650          642,412          642,412          688,734          735,056          
 + Depreciation -                        268,066             428,905          257,343          154,406          154,406          77,203             -                        
 + Loss Forward -                        -                           -                        -                        -                        -                        -                        -                        
 - Fixed Capital (1,340,329)     -                           -                        -                        -                        -                        -                        -                        
Cash Flow (1,340,329)     474,754             906,618          837,993          796,818          796,818          765,937          735,056          
Discount Factor (P/F i*,n) 1.0000 0.9091 0.8264 0.7513 0.6830 0.6209 0.5645 0.5132
Discounted Cash Flow (1,340,329)     431,595             749,271          629,597          544,237          494,761          432,351          377,200          
NPV @ i* = 2,318,683       
DCFROR = 50%
Paybock Period = 2.25                 years
5 Year MACRS Depreciation
Four Train High Production of Stem Cell Treatments
Stand Alone
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first year. The Net Present Value (NPV) for Scenarios 1 & 2 is 1.85 million dollars. The NPV for 
Scenario 3 is 2.32 million dollars. All scenarios meet the design criteria of a 50% IRR. 
A direct comparison of the critical economic considerations can be seen in Table 14: Economic 
Analysis Summary. Notice that producing cells in Scenario 1 provides the most expensive 
treatment cost. Scenario 3 offers a treatment cost that is nearly 80% cheaper than in Scenario 
1.  However, Scenario 3 produces 12 times the amount of treatments. This should be 
considered as this cell therapy treatment makes its way onto the market place. Allowing market 
forces to dictate cell production will be the best protection against over production. This means 
that initially the treatments will remain relatively expensive to what they could cost as the first 
few thousand patients undergo treatment. As the market demand for treatments increases 
cellular production should be increased. 
 
 
Figure 7: Estimated Spinal Cord Injury Treatment Costs 
The approximated annual and lifetime cost for individuals disabled due to spinal cord injury of 
varying severity is provided in the above Figure 7: Estimated Spinal Cord Injury Treatment 
Costs37.  The above graphic was provided by the Christopher & Dana Reeve Foundation. 
As can be seen when comparing the price per treatment to the expected costs for just the 
annual costs of caring for an individual suffering from a spinal cord injury let alone the lifetime 
costs it is clear that the cell therapy facility designed in this report will offer a superior 
                                                          
37
 (Foundation, 2015) 
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alternative to healthcare professionals and their patients in dealing with spinal cord injuries. 




A sensitivity analysis was performed in order to determine the effect of cost variability on the 
price of the treatment. 
Tornado Charts 
 
Figure 8: Scenario 1 Tornado Chart 
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Figure 9: Scenario 2 Tornado Chart 
 
Figure 10: Scenario 3 Tornado Chart 
The sensitivity analysis was generated by varying the same four variables in Scenario 1, 2 and 3. 
The analysis was conducted and the following tornado charts were produced for each scenario 
as seen in Figure 8: Scenario 1 Tornado Chart, Figure 9: Scenario 2 Tornado Chart, and Figure 10: 
Scenario 3 Tornado Chart. The charts look nearly identical from a qualitative perspective. This 
makes sense as changes in one scenario should have a similar magnitude of effect in the other 
scenarios. 
The first of these variables is the total amount of treatments produced per run. It was varied 
from 60% in either direction. The swing in either direction is so large in order to account for 
inaccuracies that may be discovered in translating research work to manufacturing practice. 
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The second of these variables is the labor costs. It was varied up to 75% more expensive and 
41% less expensive. These percentages were determined from taking the mean annual wage of 
the top 90th percentile and the 10th percentile for each position38,39. Labor costs have the 
second most effect of all the variables measured. 
The third variable is the capital costs. Capital costs were varied by 20% in either direction and 
found to have the second to least effect of all the variables measured. The 20% movement in 
either direction is to account for changes in the market and mismatched pricing data collected 
from the internet when compared with quotes received from companies in detailed design. 
This analysis would suggest that the price of the capital costs has little effect on the final price 
of the treatments.  
The last variable is the raw material costs. These were varied by 20% in either direction and 
found to have the least effect of all the variables measured. This analysis would suggest that 
raw materials cost variability has little effect on the final treatment price. 
Monte Carlo Simulation 
 
The Monte Carlo simulation was run using @Risk 7.0 with same variables that were used to 
develop the tornado charts. All variables were assumed to have a normal distribution, due to 
the lack of historical data and trends in this sector. The mean of each distribution in the 
simulation was the original calculated value for that variable. The standard deviation was 
assumed to be 10% of the original value for all variables except for the number of treatments in 
which the standard deviation was assumed to be 30% so as to allow for 95% of the values to fall 
between 60% on either side. The name of the university with the course license has been 
redacted from the graphs for anonymity.  
                                                          
38
 (Statistics, 2014a) 
39
 (Statistics, 2014b) 
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Figure 11: Scenario 1 Monte Carlo Simulation 
 
Figure 12: Scenario 2 Monte Carlo Simulation 
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Figure 13: Scenario 3 Monte Carlo Simulation 
The Monte Carlo simulation for Scenario 1 can be seen in Figure 11: Scenario 1 Monte Carlo 
Simulation , for Scenario 2 can be seen in Figure 12: Scenario 2 Monte Carlo Simulation and in 
Scenario 3 can be seen in Figure 13: Scenario 3 Monte Carlo Simulation. An analysis of the 
simulation shows that as the number of treatments increases the variability of price decreases. 
This is a result of the increased amount of treatments being sold that attenuates any 
fluctuations in variable prices. 
The prices tend to cluster around the mean price. The Monte Carlo simulation demonstrates 
that with a 95% of the time the price of the treatment is not more than double the originally 
calculated price. Finally, the Monte Carlo simulation demonstrates that at all values it projected 
the cell therapy would still be a superior alternative, both economically and based on quality of 
life, to traditional spinal cord injury care. This results in very high confidence that the facility will 
be economically successful. 
Other Important Considerations 
Virus Inactivation 
 
An important consideration is the inactivation of virus before they enter the manufacturing 
process. The majority of the media is feeder-free and therefore will be sterile (at least it is 
assumed to be) upon arrival to the clean room. The exception to this is the neural induction 
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media. It comes from human plasma and therefore must be irradiated in order to inactivate any 
potential viruses before its addition to the cellular solutions. 
Table 29: Virus Inactivation UV-C Dosage 
 
 
Figure 14: Log Kill of Viruses 
The dosage to kill a 99.9% of viruses was inferred from a UV sterilization manufacturer40. This dosage 
was scaled as seen in Table 14 to kill 99.999% of viruses in the media. Based on available literature this 
dosage is found to be acceptable to treating the media with minimal effect seen in the cells41. 
Timing of Batch Processes 
Another important consideration is what the batch process will look like during operation. The 
Gantt charts provided in Figure 1: Low Production Gantt Chart and Figure 2 offer a good overview 
of how the equipment is used during the process. 
                                                          
40
 (Solutions, 2016) 
41
 (Yen et al., 2014) 
Percent Inactivation Log inactivation Virus UV dosage (mJ/cm^2) Require radiation time (min) 44.1
0.5 39 Power usage (W) 180
90 1 58 Runs/day 4
1.5 79 Power consumption (kW*hr) 0.53































Virus Log Inactivation 
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Figure 15: Process Schedule for High Production 
 
Figure 16: Process Schedule for Low Production 
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Above in Figure 15 and Figure 16 the process schedule for high and low production is provided. This 
provides a visually representation of each step that the cells go through.  
 
Figure 17: Operation Schedule 
In Figure 17 the majority of the steps that a technician would need to go through during a 
manufacturing campaign are provided. This will look the same for high and low production with 
regards to a single batch. In high production, the technician will need to attend to other 
batches in the interim of this schedule.   
While significant work has gone into reading, understanding, and verifying the claims (a 
combination of reasonability coupled with other papers) provided in these papers the exact 
production levels are certain to change and adaptions to the operation of the process should be 
a natural occurrence as the company gains experience with this type of design. 
 




Table 30: Quality Control Costs 
 
Quality control is critical to ensuring that the cells that are sent off as treatment are actually 
NPCs. In order to make sure that they are this quality control scheme has been developed. First, 
the QC-1 gives a total cell density and a viable cell density. This allows the facility to know how 
to adjust if they have too many or too few cells being produced. This will be critical in the 
beginning stages of the facility as data is being collected to optimize the process. QC-2 is a real 
time polymerase chain reaction which allows for testing to occur at the end of BR-2. It will first 
show that the adult stem cells are still iPSCs and haven’t yet differentiated. It can also be used 
to prove that the cells haven’t mutated and will not cause cancer in the patients. At the end of 
BR-3 QC-2 can be used to prove that proper differentiation has occurred.  
This process of quality control is more time efficient than the majority of other quality control 
processes as it allows for results to be determined within the hour as opposed to days or 
weeks. This allows contaminated batches to be quickly identified and removed and therefore 
reduces the risks of a bad batch being sent out as well as reducing the costs associated with 
having a contaminated batch. 
Conclusions 
 
This design report outlines the necessary equipment, materials, and operational considerations 
to operate a stem cell manufacturing facility. Starting with the extensive research into the topic 
to ensure the best estimations could be provided when making engineering decisions to the 
rigorous health and safety analysis and protocols this facility has technical merit and is a 
feasible project to undertake. Furthermore, the operational flexibility afforded to the company 
due to the unique module design of the facility and its contained bio-reactor trains allow this 
project to have potential success in many markets. From an economic perspective this project is 
attractive as all three operational scenarios were able to achieve a 50% IRR while stile 
producing a treatment at low cost. Even assuming worst case scenarios for the sensitivity 
analysis the treatment still provided economically attractive results. The treatment’s cost is 
Item cost size units
Cell counter (QC-1) 15,000.00$ N/A 1
NucleoCassettes 370.00$       100 cassettes
Reagent A100 73.50$          500 ml
Cell Analyzer (QC-2) 30,900.00$ N/A 1
Wellplate for cell checker - Growth 284.00$       1 assay
RNA Kit 4,680.00$    400 rxns
RNA Test Wellplate - Diff 284.00$       1 assay
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especially low when compared to the cost of living with spinal cord damage and the quality of 




The first recommendation from this project is that it moves on to detailed design. When moving 
to detailed design special consideration should be given to the protocols and operating 
procedures the technicians will follow as they offer one of the most successful ways to prevent 
injury to facility personnel and prevent contamination of the cell batches.  
Another recommendation is that the process starts with a single module with one train 
producing cells. This will allow healthcare professionals and patients to begin testing the 
effectiveness of this treatment. The company will also be able to gather more data specific to 
this application to ensure that the assumptions made and values taken from the literature hold 
true in a larger production context. This also reduces the variability in the number of 
treatments produced per batch which allows for a more consistent economic analysis to occur 
because cell treatments produced per batch had the largest effect on the price of the 
treatment. 
Lastly, the company should actively attempt to optimize this process. The optimization should 
first start with the stem cell growth process and then turn to the differentiation process. As 
everything develops the company will be able to assume a position in which it can manufacture 
other types of cell therapies in order to capitalize on their expertise in this technology.  
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Appendix A: Energy Calculations 
 
Assumed properties for these calculations: 
 
 
This calculates how much energy is required to heat the initial vial of cells from their frozen 
condition to 37°C in a water bath. 
 
This calculates how much energy is required to heat media in the water bath. This would be 
used before the media can be added to the cells in their reactors. 
Density (g/mL) 1.02
Heat capacity (J/g*K) 3.99
Media Properties (Based on data for salt water) Mass of a cell (kg) 1.00E-12
Density of a cell (g/mL) 1.05






Starting temperature (oC) -130 Starting water temp (oC) 25
Final temperature (oC) 37 Final water temp (oC) 37
Q (J) 679.71 Heater wattage (W) 360
Initial heating required (J) 0
Heat lost to vial (J) -679.71
Heat added by heater (J) 679.71
Time heating (min) 0.03
One vial Water bath
Cell thaw
Starting temperature (oC) 25 Starting water temp (oC) 25
Final temperature (oC) 37 Final water temp (oC) 37
Q/m (J/g) 47.88 Heater wattage (W) 360
Q/V (J/mL) 48.84 Initial heating required (J) 501480
Initial heating time (min) 23.22
Heat lost to media (J/mL) -48.84
Heat added by heater (J/mL) 48.84
Time heating (min/mL) 0.0023
Media preheat
One mL of media Water bath
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This calculates the total amount of energy the water bath will use in a year. This is then used to 
determine the utility cost of the water bath.  
 
This is for QC-1. It calculates the amount of energy that it uses over the course of a year. It 
comes out to less than a penny. 
 
This determines how much energy is expended by F-3 to get the treatment down from room 
temperature to -50°C. 
 
This is an energy calculation to determine how much energy is expended by F-4 to get a single 
treatment vial from -50°C to -195°C. 
Total Media/batch (mL) 55437
Total Heating time/batch (hr) 2.09
Time preheating bath (hr/year) 141.23
Heater power supply (W) 1032
Energy used/year (kW*hr) 211.35
Cost of energy ($/year) $10.57
Total Water Bath Usage
Time of test (s) 30
# of tests per batch 4
Test power consumption (W) 25
Standby  power consumption (W) 0.002
Running time (hr/year) 1.01
Down-time (hr/year) 8755.94
Total Enegry use (kW*hr/batch) 0.043
Electricty cost ($/year) $0.00
Cell Counter Energy
Starting temperature (oC) 37





Starting temperature (oC) -50 Mass evaporated (g/vial) 0.014
Final temperature (oC) -195 Vol. evaporated (uL/vial) 17.38
Q (J/vial) -1190.31 Q (J/vial) 2186.54
Qcold+Qhot 9.96E+02 Total mass lost (g/batch) 2.08
One treatment vial N2 in cooler
Cell cryopreservation
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The above table is the calculation for the electricity costs for all of the equipment. The powers 
were found in the user manuals for the equipment that was used to estimate capital costs. 
Where power was unable to be found, the voltage and the amperage were multiplied together 
to approximate the power usage of the equipment. The time for running depends upon the 
type of equipment. Most capital equipment was running year round and the other energy 
calculations were used to find the running times for the equipment that did not run year round. 
  
Electricity Cost ($/kW*hr) 0.05$           
Voltage (V) Amperage (A) Power (W) Power (kW) Time running (hrs) Cost/year
Bioreactor 1 - magnetic stirrer 1050 1.05 8760 459.90$     
Bioreactor 2 110 3.8 418 0.418 8760 183.08$     
Differential Reactor 110 3.8 418 0.418 8760 183.08$     
Fume Hood 261 0.261 8760 114.32$     
Incubater 460 0.46 8760 201.48$     
Refrigerator 115 9.4 1081 1.081 2920 157.83$     
Freezer 115 8 920 0.92 2920 134.32$     
minus 80 C freezer 115 20 2300 2.3 2920 335.80$     
UV Irradiator 180 0.18 1073 9.66$          
UV Cabinet 105 0.105 8760 45.99$       
Big Centerfuge 260 0.26 1 0.01$          
Water Bath 120 8.6 1032 1.032 499 25.76$       
Cell Counter Running 25 0.025 1 0.00$          
Cell Counter Waiting 0.002 0.000002 8759 0.00$          
Cell Analyzer 10 0.01 37 0.02$          
Autoclaver 1400 1.4 46 3.19$          
Total 1,854.44$ 
Electricity Consumption
Page 54 of 58 
 
Appendix B: Media and Operating Cost Calculations 
 
  
The above were used to calculate the amount of media, microcarriers and trypsin used on a per 
batch basis. 
 
This was used to calculate all of the consumables used on a per batch basis. 
 
This shows the price per quantity for the major chemicals that will be used in the process along 
with their consumption rates. This was used to estimate the price per year of these chemicals. 
  
Media Equipment Volume used (mL) Microcarriers used (mg) Growth area (cm²) TrypLE Express Used (mL) Microcarriers used (mg)
2ml WP1 14.8 n/a 8.8 0.587 -
30ml WP2 222 n/a 38.4 2.560 -
50ml BR1 250 400 1080 72.000 0.4
350ml BR2 1750 2400 6480 432.000 2.4
4L BR3 24200 n/a n/a n/a -
5L BR3 29000 n/a n/a n/a -
Density (mg/mL) 8
Growth area (cm²/mg) 2.7
Microcarriers
Dosage (mL/cm²) 0.0667
Price ($) 0.11$                                     
TrypLE Express
Consumable Price Quantity Unit Price/quantity quantity/batch
Ethanol 111.60$            20 L 5.58$                         9.85 L
WP1 398.10$            500 count 0.80$                         1 count
WP2 255.60$            100 count 2.56$                         1 count
Microcarriers 12,700.00$      3000 g 4.23$                         2.8 g
Microcarrier Prep 27.00$               500 ml 0.05$                         700 ml
40 micron filter - falcon cell strainer 104.00$            25 count 4.16$                         8 count
Falcon 50 mL conical centerfuge tubes 355.00$            500 count 0.71$                         16 count
100 micron filter 104.00$            25 count 4.16$                         8 count
400 micron filter 104.00$            25 count 4.16$                         8 count
cryovials 357.60$            500 count 0.72$                         148 vials
cyropreservation media 205.00$            100 ml 2.05$                         296 ml
Liquid Nitrogen Bath holders/shippers 254.00$            1620 vial spots 0.16$                         148 vials
Growth media 299.00$            500 mL 0.60$                         2236.8 mL
Neural induction media 395.00$            500 mL 0.79$                         24200 mL
Rosette selection media 35.00$               100 mL 0.35$                         29000 mL
Consumable Price ($) Quantity Units Price/unit ($) Quantity/day Price/year ($)
Liquid Nitrogen 232.82$            230 L 1.01$                         0.85 314.05$                                
CO2 28.31$               12376 L 0.00$                         35.3 29.47$                                   
Per Year Consumption
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Appendix C: Other Utility Costs 





Water Cost ($/L) 0.000543$          
Water Usage Volume (L/day) Days Volume/year (L) Price/year ($)
Water Bath 10 365 3650 1.98$                
Water Consumption
Water for Injections Cost ($/L) 1.00$                    
Use Volume (L) Units Volume (L/year)
Incubater 5.6775 per week 52 weeks 295.23 295.23$  per year
Autoclaver 1.65 per batch 30.41666667 batch/year 50.1875 50.19$    per year
Rinsing Sterilization 9.85 per batch 9.85$      per batch
Water for Injection Consumption
Yearly usage Price ($)
Sewage Cost ($/L) 0.00132$             
Sewage Use Volume (L)
Water from water bath 3650 4.83$      per year
Media After Autoclave 55.4368 0.07$      per batch
Water for Autoclave 1.65 0.0022$  per batch
Sewage Use
price
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Appendix D: Pricing Information 
 
This appendix contains all of the websites that were used to gather pricing information. These 
prices were on equipment and materials that would be similar to the equipment and materials 
that would be used in this facility. 
Growth media: http://www.stemcell.com/en/Products/Product-Type/Specialized-cell-culture-
media/TeSR2.aspx 
Neural induction media: http://www.stemcell.com/en/Products/All-Products/STEMdiff-Neural-
Induction-Medium.aspx 




Well plate 1: http://www.fishersci.com/shop/products/thermo-scientific-nunc-dishes-cell-culture-petri-
35mm-dish-airvent-500-cs/1256591 
Well plate 2: http://www.sigmaaldrich.com/catalog/product/sigma/m8562?lang=en&region=US 
Microcarriers:  
PBS: http://www.stemcell.com/en/Products/All-Products/DPBS-without-Ca-and-Mg.aspx 
40µm filter: https://www.pluriselect.com/cell-strainer.html 
50mL centrifuge tubes: https://www.fishersci.com/shop/products/falcon-50ml-conical-centrifuge-
tubes-2/p-193321#tab1 































Bioreactors: AIChE provided GE Spreadsheet 





-80ºC freezer: http://www.thermoscientific.com/en/product/80-c-benchtop-freezer.html 
In-lab UV cabinet: http://www.csiequipment.com/csi-uv-box-uvb-15_p31597.aspx 
Labor: http://www.bls.gov/ooh/life-physical-and-social-science/biological-technicians.htm; 
http://www.bls.gov/ooh/life-physical-and-social-science/medical-scientists.htm 
Autoclave: http://socalbiomedical.com/tuttnauer-ez9-ez10-series-fully-automatic-benchtop-
autoclaves.html 
